Larimar Therapeutics
LRMR
80 hedge funds and large institutions have $66.1M invested in Larimar Therapeutics in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 32 reducing their positions, and 7 closing their positions.
106% more call options, than puts
Call options by funds: $377K | Put options by funds: $183K
52% more capital invested
Capital invested by funds: $43.4M → $66.1M (+$22.7M)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
0.16% more ownership
Funds ownership: 4.16% → 4.32% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 81 → 80 (-1)
22% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.5M |
| 2 |
AG
Artal Group
Luxembourg
|
+$2.07M |
| 3 |
JP Morgan Chase
New York
|
+$1.85M |
| 4 |
Renaissance Technologies
New York
|
+$746K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$887K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$750K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$701K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$690K |
| 5 |
SIM
Spark Investment Management
New York
|
-$678K |
LRMR Hedge Fund Activity: Q1 2017 in Review
80 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2017, worth a combined $66.1M — up 52% from $43.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LRMR positions and 7 closed out — a net gain of 3 holders — while 25 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $5.5M. The largest seller was Foresite Capital Management II, cutting an estimated $887K.
- 80 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2017, down from 81 in Q4 2016.
- Funds reported $66.1M of Larimar Therapeutics stock for Q1 2017, up 52% quarter-over-quarter.
- 10 funds opened new Larimar Therapeutics positions in Q1 2017 and 7 closed out, a net change of +3 holders.
- The largest Larimar Therapeutics buyer in Q1 2017 was BlackRock, an estimated $5.5M added.
- The largest Larimar Therapeutics seller in Q1 2017 was Foresite Capital Management II, an estimated $887K sold.
Based on aggregated 13F filings for Q1 2017.